| [1] |
Siegel RL, Miller KD, Fuchs HE, et al.
Cancer statistics, 2022[J]. CA Cancer J ClinCA Cancer J Clin, 2022, 72(1): 7-33.
doi: 10.3322/caac.21708 |
| [2] |
Du LB, Zhao ZX, Zheng RS, et al. Epidemiology of thyroid cancer: incidence and mortality in China, 2015[J/OL]. Front Oncol, 2020, 10: 1702[2022-04-24]. https://www.frontiersin.org/articles/10.3389/fonc.2020.01702/full. DOI: 10.3389/fonc.2020.01702. |
| [3] |
Fraser S, Zaidi N, Norlén O, et al.
Incidence and risk factors for occult level 3 lymph node metastases in papillary thyroid cancer[J]. Ann Surg OncolAnn Surg Oncol, 2016, 23(11): 3587-3592.
doi: 10.1245/s10434-016-5254-8 |
| [4] |
张浩.
分化型甲状腺癌术后复发的处理策略[J]. 中华普外科手术学杂志: 电子版中华普外科手术学杂志: 电子版, 2016, 10(5): 373-375.
doi: 10.3877/cma.j.issn.1674-3946.2016.05.004 Zhang H. Management of recurrent nodal disease in patients with differentiated thyroid cancer[J]. Chin J Oper Proc Gen Surg (Electron Ed)Chin J Oper Proc Gen Surg (Electron Ed), 2016, 10(5): 373-375. doi: 10.3877/cma.j.issn.1674-3946.2016.05.004 |
| [5] |
Duong T, Koopman P, Francois M.
Tumor lymphangiogenesis as a potential therapeutic target[J]. J OncolJ Oncol, 2012, 2012: 204946-.
doi: 10.1155/2012/204946 |
| [6] |
Stacker SA, Williams SP, Karnezis T, et al.
Lymphangiogenesis and lymphatic vessel remodelling in cancer[J]. Nat Rev CancerNat Rev Cancer, 2014, 14(3): 159-172.
doi: 10.1038/nrc3677 |
| [7] |
Gogineni A, Caunt M, Crow A, et al. Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis[J/OL]. PLoS One, 2013, 8(7): e68755[2022-04-24]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0068755. DOI: 10.1371/journal.pone.0068755. |
| [8] |
Jeltsch M, Kaipainen A, Joukov V, et al.
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice[J]. ScienceScience, 1997, 276(5317): 1423-1425.
doi: 10.1126/science.276.5317.1423 |
| [9] |
Alitalo A, Detmar M.
Interaction of tumor cells and lymphatic vessels in cancer progression[J]. OncogeneOncogene, 2012, 31(42): 4499-4508.
doi: 10.1038/onc.2011.602 |
| [10] |
Alitalo K, Carmeliet P.
Molecular mechanisms of lymphangiogenesis in health and disease[J]. Cancer CellCancer Cell, 2002, 1(3): 219-227.
doi: 10.1016/s1535-6108(02)00051-x |
| [11] |
Jang JY, Kim DS, Park HY, et al.
Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma[J]. Head NeckHead Neck, 2019, 41(8): 2602-2609.
doi: 10.1002/hed.25729 |
| [12] |
Yasuoka H, Nakamura Y, Zuo H, et al.
VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma[J]. Mod PatholMod Pathol, 2005, 18(8): 1127-1133.
doi: 10.1038/modpathol.3800402 |
| [13] |
Bumber B, Marjanovic Kavanagh M, Jakovcevic A, et al.
Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer[J]. Clin OtolaryngolClin Otolaryngol, 2020, 45(1): 55-62.
doi: 10.1111/coa.13466 |
| [14] |
中华人民共和国国家卫生健康委员会.
甲状腺癌诊疗规范(2018年版)[J]. 中华普通外科学文献: 电子版中华普通外科学文献: 电子版, 2019, 13(1): 1-15.
doi: 10.3877/cma.j.issn.1674-0793.2019.01.001 National Health Commission of the People's Republic of China. Diagnosis and treatment guidelines for thyroid cancer (2018 edition)[J]. Chin Arch Gen Surg (Electron Ed)Chin Arch Gen Surg (Electron Ed), 2019, 13(1): 1-15. doi: 10.3877/cma.j.issn.1674-0793.2019.01.001 |
| [15] |
Attard A, Paladino NC, Lo Monte AI, et al. Skip metastases to lateral cervical lymph nodes in differentiated thyroid cancer: a systematic review[J/OL]. BMC Surg, 2019, 18(S1): S112[2022-04-24]. https://bmcsurg.biomedcentral.com/articles/10.1186/s12893-018-0435-y. DOI: 10.1186/s12893-018-0435-y. |
| [16] |
Liu CX, Xiao C, Chen JJ, et al. Risk factor analysis for predicting cervical lymph node metastasis in papillary thyroid carcinoma: a study of 966 patients[J/OL]. BMC Cancer, 2019, 19(1): 622[2022-04-24]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5835-6. DOI: 10.1186/s12885-019-5835-6. |
| [17] |
Sakorafas GH, Koureas A, Mpampali I, et al.
Patterns of lymph node metastasis in differentiated thyroid cancer; clinical implications with particular emphasis on the emerging role of compartment-oriented lymph node dissection[J]. Oncol Res TreatOncol Res Treat, 2019, 42(3): 143-147.
doi: 10.1159/000488905 |
| [18] |
Zhao HQ, Huang T, Li HH.
Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer[J]. SurgerySurgery, 2019, 166(1): 55-60.
doi: 10.1016/j.surg.2019.01.025 |
| [19] |
Lin P, Yao ZN, Sun Y, et al.
Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples[J]. J ProteomicsJ Proteomics, 2019, 204: 103414-.
doi: 10.1016/j.jprot.2019.103414 |
| [20] |
Zhan SH, Wang TX, Wang M, et al.
In-depth proteomics analysis to identify biomarkers of papillary thyroid cancer patients older than 45 years with different degrees of lymph node metastases[J]. Proteomics Clin ApplProteomics Clin Appl, 2019, 13(5): e1900030-.
doi: 10.1002/prca.201900030 |
| [21] |
Xing ZC, Qiu YX, Yang QR, et al.
Thyroid cancer neck lymph nodes metastasis: meta-analysis of US and CT diagnosis[J]. Eur J RadiolEur J Radiol, 2020, 129: 109103-.
doi: 10.1016/j.ejrad.2020.109103 |
| [22] |
Tian XQ, Song Q, Xie F, et al.
Papillary thyroid carcinoma: an ultrasound-based nomogram improves the prediction of lymph node metastases in the central compartment[J]. Eur RadiolEur Radiol, 2020, 30(11): 5881-5893.
doi: 10.1007/s00330-020-06906-6 |
| [23] |
Hwang HS, Orloff LA.
Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer[J]. LaryngoscopeLaryngoscope, 2011, 121(3): 487-491.
doi: 10.1002/lary.21227 |
| [24] |
Xu YX, Wu DP, Wu WT, et al.
Diagnostic value of cytology, thyroglobulin, and combination of them in fine-needle aspiration of metastatic lymph nodes in patients with differentiated thyroid cancer: a systematic review and network meta-analysis[J]. Medicine (Baltimore)Medicine (Baltimore), 2019, 98(45): e17859-.
doi: 10.1097/MD.0000000000017859 |
| [25] |
Suh CH, Baek JH, Choi YJ, et al.
Performance of CT in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid cancer: a systematic review and meta-analysis[J]. AJNR Am J NeuroradiolAJNR Am J Neuroradiol, 2017, 38(1): 154-161.
doi: 10.3174/ajnr.A4967 |
| [26] |
He MZ, Lin CL, Yin L, et al.
Value of dual-energy computed tomography for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer[J]. J Comput Assist TomogrJ Comput Assist Tomogr, 2019, 43(6): 970-975.
doi: 10.1097/RCT.0000000000000927 |
| [27] |
Yeh MW, Bauer AJ, Bernet VA, et al.
American Thyroid Association statement on preoperative imaging for thyroid cancer surgery[J]. ThyroidThyroid, 2015, 25(1): 3-14.
doi: 10.1089/thy.2014.0096 |
| [28] |
Hu WJ, Wang H, Wei R, et al.
MRI-based radiomics analysis to predict preoperative lymph node metastasis in papillary thyroid carcinoma[J]. Gland SurgGland Surg, 2020, 9(5): 1214-1226.
doi: 10.21037/gs-20-479 |
| [29] |
Zhang H, Hu SD, Wang X, et al. Using diffusion-weighted MRI to predict central lymph node metastasis in papillary thyroid carcinoma: a feasibility study[J/OL]. Front Endocrinol (Lausanne), 2020, 11: 326[2022-04-24]. https://www.frontiersin.org/articles/10.3389/fendo.2020.00326/full. DOI: 10.3389/fendo.2020.00326. |
| [30] |
Xu QF, Liu RC, Wang J, et al.
Role of [99mTc]Tc-Galacto-RGD2 SPECT/CT in identifying metastatic differentiated thyroid carcinoma after thyroidectomy and radioactive iodine therapy[J]. Nucl Med BiolNucl Med Biol, 2020, 88-89: 34-43.
doi: 10.1016/j.nucmedbio.2020.06.006 |
| [31] |
Kim DH, Kim SJ.
Diagnostic role of F-18 FDG PET/CT for preoperative lymph node staging in thyroid cancer patients; A systematic review and metaanalysis[J]. Clin ImagingClin Imaging, 2020, 65: 100-107.
doi: 10.1016/j.clinimag.2020.04.030 |
| [32] |
Zheng K, Liang NX, Zhang JJ, et al.
68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer[J]. J Nucl MedJ Nucl Med, 2015, 56(12): 1823-1827.
doi: 10.2967/jnumed.115.160648 |
| [33] |
徐震纲, 刘绍严.
分化型甲状腺癌颈侧区淋巴结清扫专家共识(2017版)[J]. 中国实用外科杂志中国实用外科杂志, 2017, 37(9): 985-991.
doi: 10.19538/j.cjps.issn1005-2208.2017.09.13 Xu ZG, Liu SY. Expert consensus on cervical lymph node dissection for differentiated thyroid carcinoma (2017 edition)[J]. Chin J Pract SurgChin J Pract Surg, 2017, 37(9): 985-991. doi: 10.19538/j.cjps.issn1005-2208.2017.09.13 |
| [34] |
Megwalu UC, Orloff LA, Ma YF.
Adjuvant external beam radiotherapy for locally invasive papillary thyroid cancer[J]. Head NeckHead Neck, 2019, 41(6): 1719-1724.
doi: 10.1002/hed.25639 |
| [35] |
Roh JL, Kim JM, Park CI.
Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia[J]. Ann Surg OncolAnn Surg Oncol, 2011, 18(5): 1312-1318.
doi: 10.1245/s10434-010-1470-9 |
| [36] |
Ilhan H, Mustafa M, Bartenstein P, et al.
Rate of elimination of radioiodineavid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study[J]. NuklearmedizinNuklearmedizin, 2016, 55(6): 221-227.
doi: 10.3413/Nukmed-0794-16-01 |
| [37] |
Wu XY, Gu H, Gao YJ, et al.
Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma[J]. Nucl Med CommunNucl Med Commun, 2018, 39(1): 22-27.
doi: 10.1097/MNM.0000000000000777 |
| [38] |
He Y, Pan MZ, Huang JM, et al.
Iodine-131: an effective method for treating lymph node metastases of differentiated thyroid cancer[J]. Med Sci MonitMed Sci Monit, 2016, 22: 4924-4928.
doi: 10.12659/msm.899028 |
| [39] |
Lewis BD, Hay ID, Charboneau JW, et al.
Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2002, 178(3): 699-704.
doi: 10.2214/ajr.178.3.1780699 |
| [40] |
Heilo A, Sigstad E, Fagerlid KH, et al.
Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2011, 96(9): 2750-2755.
doi: 10.1210/jc.2010-2952 |
| [41] |
Kim SY, Kim SM, Chang H, et al.
Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer[J]. Eur Arch OtorhinolaryngolEur Arch Otorhinolaryngol, 2017, 274(9): 3497-3501.
doi: 10.1007/s00405-017-4660-2 |
| [42] |
Fontenot TE, Deniwar A, Bhatia P, et al.
Percutaneous ethanol injection vs. reoperation for locally recurrent papillary thyroid cancer: a systematic review and pooled analysis[J]. JAMA Otolaryngol Head Neck SurgJAMA Otolaryngol Head Neck Surg, 2015, 141(6): 512-518.
doi: 10.1001/jamaoto.2015.0596 |
| [43] |
Guang Y, Luo YK, Zhang Y, et al.
Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma[J]. J Cancer Res Clin OncolJ Cancer Res Clin Oncol, 2017, 143(8): 1555-1562.
doi: 10.1007/s00432-017-2386-6 |
| [44] |
Mauri G, Cova L, Ierace T, et al.
Treatment of metastatic lymph nodes in the neck from papillary thyroid carcinoma with percutaneous laser ablation[J]. Cardiovasc Intervent RadiolCardiovasc Intervent Radiol, 2016, 39(7): 1023-1030.
doi: 10.1007/s00270-016-1313-6 |